Buprenorphine/naloxone - one formulation that doesn't fit all: a case report
Abstract Background Sublingual buprenorphine, approved for treatment of opioid use disorder since 2002, is most commonly available in co-formulation with naloxone. Naloxone is an opioid antagonist minimally absorbed when sublingual (SL) buprenorphine/naloxone is taken as prescribed; it is thought to...
Sábháilte in:
Príomhchruthaitheoirí: | , , |
---|---|
Formáid: | LEABHAR |
Foilsithe / Cruthaithe: |
BMC,
2024-07-01T00:00:00Z.
|
Ábhair: | |
Rochtain ar líne: | Connect to this object online. |
Clibeanna: |
Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|
Ar líne
Connect to this object online.3rd Floor Main Library
Gairmuimhir: |
A1234.567 |
---|---|
Cóip 1 | Ar fáil |